Roche's Avastin Combination Therapy Demonstrates Significant Overall Survival Benefit in Phase 2 Study of Endometrial Cancer
Clinical Trial Design and Objectives of the Combination Therapy
The GOG-86P Phase 2 clinical trial, led by the National Cancer Institute (NCI), was designed to improve survival rates in patients with advanced or recurrent endometrial cancer, a condition with poor prognosis. The trial evaluated three experimental arms that combined the standard chemotherapy regimen of paclitaxel and carboplatin with targeted therapies. Specifically, it compared Roche's angiogenesis inhibitor bevacizumab (Avastin) in combination with the chemotherapy, Pfizer's mTOR inhibitor temsirolimus (Torisel), and Bristol Myers Squibb's (BMS) ixabepilone (Ixempra) in combination with bevacizumab. This was an attempt to overcome the limitations of single-agent chemotherapy and to inhibit the tumor microenvironment in multiple ways.
Survival Data Analysis and Asymmetrical Efficacy
The clinical analysis revealed that none of the three experimental arms achieved a significant improvement in progression-free survival (PFS) compared to the historical control group (GOG-209 trial). However, in terms of overall survival (OS), only the first arm (paclitaxel/carboplatin/bevacizumab) demonstrated a survival benefit, with a hazard ratio (HR) of 0.71 (92% CI, 0.55-0.91). The OS hazard ratio for the temsirolimus combination arm was 0.99 (92% CI, 0.78-1.26), and for the ixabepilone combination arm, it was 0.97 (92% CI, 0.77-1.23), showing no difference compared to the control group. These results are considered key data demonstrating that the angiogenesis inhibition mechanism is effective in improving long-term survival in endometrial cancer patients.
Landscape of the Endometrial Cancer Market and the Rise of Competing Drugs
The global endometrial cancer treatment market is estimated at approximately $21.4 billion in 2024, based on the top 7 countries (United States, 4 European countries, United Kingdom, and Japan), and is expected to grow to approximately $31.5 billion by 2035. Although the GOG-86P trial demonstrated the efficacy of bevacizumab, the current standard of care in the market has shifted rapidly to immune checkpoint inhibitors. MSD's pembrolizumab (Keytruda) and Eisai's lenvatinib (Lenvima) combination therapy, as well as GSK's dostarlimab (Jemperli), have been approved by the FDA as first-line treatments. As a result, bevacizumab combination therapy is now primarily prescribed for patients who are not eligible for immunotherapy or who have specific biomarkers.
TP53 Biomarker and Expansion of Precision Medicine
Post-hoc biomarker analysis conducted after the completion of the clinical trial revealed that patients with TP53 mutations and p53 protein overexpression derived greater OS benefits from the bevacizumab combination therapy. This provides critical evidence supporting the need for the introduction of precision medicine based on gene profiling in the treatment of endometrial cancer. Recent clinical development trends in endometrial cancer are evolving towards stratifying patients based on mismatch repair deficiency (dMMR/MSI-H) status and p53 status, and providing targeted therapy accordingly. Ultimately, the GOG-86P trial has laid the groundwork for precision genetic-based clinical trial designs that identify the optimal targeted therapy combinations for specific genetically defined patient populations.
The overall survival (OS) hazard ratio of 0.71 achieved by the bevacizumab combination therapy in the GOG-86P Phase 2 clinical trial for advanced endometrial cancer provides an important milestone for the design of subsequent Phase 3 trials and the development of combination therapies. In the global endometrial cancer treatment market, which is estimated at $21.4 billion in 2024, the demonstration of OS improvement with bevacizumab expands the potential for combination with immune checkpoint inhibitors such as MSD's Keytruda and GSK's Jemperli, which are now established as standard treatments. In the short term, it contributes to the development of precision treatment strategies for specific biomarker (e.g., p53 overexpression) patient populations, and in the medium to long term, it is expected to promote off-label use of bevacizumab and the growth of the biosimilar market. As a result, the findings of this clinical trial serve as a powerful catalyst for the development of next-generation targeted and immunotherapies based on molecular biological mechanisms, overcoming the limitations of simple chemotherapy in the treatment of endometrial cancer.
Source: ClinicalTrials.gov (api_ct)